NCT06991556 2026-04-16
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Novartis
Phase 2 Recruiting
Clinical Trials
14 trialsNCT07226986 2026-04-16
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Novartis
Phase 1/2 Recruiting
NCT07237269 2026-04-15
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
University of Nebraska
Phase 2 Recruiting
NCT06220864 2026-04-14
SNV1521 in Participants With Advanced Solid Tumors
Synnovation Therapeutics, Inc.
Phase 1 Recruiting
NCT06592924 2026-04-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT02772588 2026-04-13
AASUR in High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT06863272 2026-04-13
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04787744 2026-04-08
VA STARPORT
VA Office of Research and Development
Phase 2/3 Recruiting
NCT07190300 2026-04-08
TulmiSTAR-02
Novartis
Phase 1/2 Recruiting
NCT07287150 2026-04-08
InavoPC
Hoffmann-La Roche
Phase 2 Recruiting
NCT06145308 2026-04-02
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT04221542 2026-03-30
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Amgen
Phase 1 Recruiting
NCT06832774 2026-03-25
Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT06421935 2026-03-24
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
EMD Serono
Phase 1 Active not recruiting